Ann Intern Med

1. BUTT AA, Omer SB, Yan P, Shaikh OS, et al
   SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting.
   Ann Intern Med. 2021 Jul 20. doi: 10.7326/M21-1577.
   

   >> Share

   
   

   
   BMJ

2. MAHASE E
   Covid-19: Vulnerable children aged 12-15 will be offered Pfizer vaccine, UK announces.
   BMJ. 2021;374:n1841.
   

   >> Share

   
   
3. IACOBUCCI G
   Covid-19: Fully vaccinated NHS staff may not need to self-isolate.
   BMJ. 2021;374:n1830.
   

   >> Share

   
   

   
   Clin Infect Dis

4. LAWS RL, Biraro S, Kirungi W, Gianetti B, et al
   COVID-19 Mitigation Efforts and Testing During an In-Person Training Event - Uganda, October 12-29, 2020.
   Clin Infect Dis. 2021 Apr 29. pii: 6257593. doi: 10.1093.
   

   >> Share

   
   
5. TRAM KH, Saeed S, Bradley C, Fox B, et al
   Deliberation, Dissent, and Distrust: Understanding distinct drivers of COVID-19 vaccine hesitancy in the United States.
   Clin Infect Dis. 2021 Jul 16. pii: 6323151. doi: 10.1093.
   

   >> Share

   
   
6. ANDREJKO KL, Pry J, Myers JF, Jewell NP, et al
   Prevention of COVID-19 by mRNA-based vaccines within the general population of California.
   Clin Infect Dis. 2021 Jul 20. pii: 6324500. doi: 10.1093.
   

   >> Share

   
   
7. BOUTRY C, Hastie A, Diez-Domingo J, Tinoco JC, et al
   The Adjuvanted Recombinant Zoster Vaccine Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase III Clinical Trials (ZOE-50 and ZOE-70).
   Clin Infect Dis. 2021 Jul 20. pii: 6324611. doi: 10.1093.
   

   >> Share

   
   
8. HALBROOK M, Gadoth A, Martin-Blais R, Gray AN, et al
   Longitudinal assessment of COVID-19 vaccine acceptance and uptake among frontline medical workers in Los Angeles, California.
   Clin Infect Dis. 2021 Jul 22. pii: 6325325. doi: 10.1093.
   

   >> Share

   
   
9. WOLDEMESKEL BA, Karaba AH, Garliss CC, Beck EJ, et al
   The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV.
   Clin Infect Dis. 2021 Jul 22. pii: 6325617. doi: 10.1093.
   

   >> Share

   
   

   
   Infect Immun

10. HALL ER, O'Dowd A, Rollenhagen JE, Espinoza N, et al
    Establishment and Validation of Pathogenic CS17(+) and CS19(+) Enterotoxigenic Escherichia coli Challenge Models in the New World Primate Aotus nancymaae.
    Infect Immun. 2021;89.
    

    >> Share

    
    

    
    J Immunol

11. HUSEBY KELCHER AM, Baehr CA, Hamid FA, Hart GT, et al
    Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders.
    J Immunol. 2021 Jul 19. pii: jimmunol.2100204. doi: 10.4049/jimmunol.2100204.
    

    >> Share

    
    
12. COLE LE, Elkins KL, Michalek SM, Qureshi N, et al
    Correction: Immunologic Consequences of Francisella tularensis Live Vaccine Strain Infection: Role of the Innate Immune Response in Infection and Immunity.
    J Immunol. 2021 Jul 16. pii: jimmunol.2100505. doi: 10.4049/jimmunol.2100505.
    

    >> Share

    
    

    
    J Infect Dis

13. PETRIE JG, Bazzi LA, McDermott AB, Follmann D, et al
    Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses.
    J Infect Dis. 2021;224:49-59.
    

    >> Share

    
    
14. DEEN J, Clemens JD
    Assessment of vaccine herd protection: Lessons learned from cholera and typhoid vaccine trials.
    J Infect Dis. 2021 Jul 17. pii: 6323356. doi: 10.1093.
    

    >> Share

    
    

    
    J Pediatr

15. TEASDALE CA, Borrell LN, Kimball S, Rinke ML, et al
    Plans to Vaccinate Children for COVID-19: A Survey of Us Parents.
    J Pediatr. 2021 Jul 17. pii: S0022-3476(21)00688.
    

    >> Share

    
    

    
    J Virol

16. CARNELL GW, Ciazynska KA, Wells DA, Xiong X, et al
    SARS-CoV-2 spike protein stabilized in the closed state induces potent neutralizing responses.
    J Virol. 2021 May 7. pii: JVI.00203-21. doi: 10.1128/JVI.00203.
    

    >> Share

    
    

    
    JAMA

17. BATES TA, Leier HC, Lyski ZL, Goodman JR, et al
    Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.
    JAMA. 2021 Jul 21. pii: 2782428. doi: 10.1001/jama.2021.11656.
    

    >> Share

    
    

    
    Lancet

18. BOROBIA AM, Carcas AJ, Perez-Olmeda M, Castano L, et al
    Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lancet. 2021 Jun 25. pii: S0140-6736(21)01420.
    

    >> Share

    
    
19. THE LANCET
    COVID-19 in Latin America-emergency and opportunity.
    Lancet. 2021;398:93.
    

    >> Share

    
    
20. 
    Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00984.
    

    >> Share

    
    
21. CAUSEY K, Fullman N, Sorensen RJD, Galles NC, et al
    Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01337.
    

    >> Share

    
    
22. CAUCHEMEZ S, Bosetti P, Kiem CT, Mouro V, et al
    Education and mental health: good reasons to vaccinate children.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01453.
    

    >> Share

    
    
23. DANOVARO-HOLLIDAY MC, Kretsinger K, Gacic-Dobo M
    Measuring and ensuring routine childhood vaccination coverage.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)01228.
    

    >> Share

    
    

    
    N Engl J Med

24. EVANS SJW, Jewell NP
    Vaccine Effectiveness Studies in the Field.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMe2110605.
    

    >> Share

    
    
25. STRUYF F, Sadoff J, Douoguih M
    ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant.
    N Engl J Med. 2021;385.
    

    >> Share

    
    
26. MADHI SA, Izu A, Pollard AJ
    ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply.
    N Engl J Med. 2021;385.
    

    >> Share

    
    
27. LOPEZ BERNAL J, Andrews N, Gower C, Gallagher E, et al
    Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
    N Engl J Med. 2021 Jul 21. doi: 10.1056/NEJMoa2108891.
    

    >> Share

    
    

    
    Nat Med

28. MACHINGAIDZE S, Wiysonge CS
    Understanding COVID-19 vaccine hesitancy.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01459.
    

    >> Share

    
    
29. SOLIS ARCE JS, Warren SS, Meriggi NF, Scacco A, et al
    COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01454.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

30. KIM JH, Drame M, Puthanakit T, Chiu NC, et al
    Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6-35 Months of Age: Results From a Phase 2, Randomized, Observer-blind, Multicenter, Dose-ranging Study.
    Pediatr Infect Dis J. 2021 Jul 19. pii: 00006454-900000000-95743.
    

    >> Share

    
    
31. VAN DEN BROEK B, Coolen JPM, de Jonge MI, de Groot R, et al
    Neisseria meningitidis Serogroup Z Meningitis in a Child With Complement C8 Deficiency and Potential Cross Protection of the MenB-4C Vaccine.
    Pediatr Infect Dis J. 2021 Jul 19. pii: 00006454-900000000-95744.
    

    >> Share

    
    
32. GURUNG M, Bijukchhe SM, Hariri P, Voysey M, et al
    Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.
    Pediatr Infect Dis J. 2021 Jul 20. pii: 00006454-900000000-95740.
    

    >> Share

    
    

    
    Pediatrics

33. TINKER SC, Cogswell ME, Peacock G, Ryerson AB, et al
    Important Considerations for COVID-19 Vaccination of Children With Developmental Disabilities.
    Pediatrics. 2021 Jul 16. pii: peds.2021-053190. doi: 10.1542/peds.2021-053190.
    

    >> Share

    
    

    
    PLoS Med

34. MAO W, Ogbuoji O, Watkins D, Bharali I, et al
    Achieving global mortality reduction targets and universal health coverage: The impact of COVID-19.
    PLoS Med. 2021;18:e1003675.
    

    >> Share

    
    

    
    PLoS One

35. ALVAREZ MM, Bravo-Gonzalez S, Trujillo-de Santiago G
    Modeling vaccination strategies in an Excel spreadsheet: Increasing the rate of vaccination is more effective than increasing the vaccination coverage for containing COVID-19.
    PLoS One. 2021;16:e0254430.
    

    >> Share

    
    
36. DITOSTO JD, Weiss RE, Yee LM, Badreldin N, et al
    Association of Tdap vaccine guidelines with vaccine uptake during pregnancy.
    PLoS One. 2021;16:e0254863.
    

    >> Share

    
    
37. DUTTA S, Kumar A, Dutta M, Walsh C, et al
    Retraction: Tracking COVID-19 vaccine hesitancy and logistical challenges: A machine learning approach.
    PLoS One. 2021;16:e0255347.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

38. PETERSEN MB, Bor A, Jorgensen F, Lindholt MF, et al
    Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust.
    Proc Natl Acad Sci U S A. 2021;118.
    

    >> Share

    
    

    
    Science

39. O'GRADY C
    Sex and gender missing in COVID-19 data.
    Science. 2021;373:145.
    

    >> Share

    
    

    
    Vaccine

40. AL-SHAIKH A, Muthu N, Aidyralieva C, Profili MC, et al
    COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Vaccine. 2021 Jun 29. pii: S0264-410X(21)00840.
    

    >> Share

    
    
41. HANLY M, Churches T, Fitzgerald O, MacIntyre CR, et al
    Vaccinating Australia: How long will it take?
    Vaccine. 2021 Jul 17. pii: S0264-410X(21)00865.
    

    >> Share

    
    
42. SHILLING H, Garland SM, Atchison S, Cornall AM, et al
    Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Vaccine. 2021 Jul 16. pii: S0264-410X(21)00864.
    

    >> Share

    
    
43. MOGAJI E
    Marketing the COVID-19 vaccine and the implications for public health.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00874.
    

    >> Share

    
    
44. SCHEIBLHOFER S, Drothler S, Braun W, Braun R, et al
    Laser-facilitated epicutaneous immunization of mice with SARS-CoV-2 spike protein induces antibodies inhibiting spike/ACE2 binding.
    Vaccine. 2021;39:4399-4403.
    

    >> Share

    
    
45. O'DELL FJ, Williams AN, Poland A
    The contributions of William Money MRCS to smallpox vaccination and control - A little-known story.
    Vaccine. 2021 Jul 13. pii: S0264-410X(21)00844.
    

    >> Share

    
    
46. MACINTYRE CR, Veness B, Berger D, Hamad N, et al
    Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia.
    Vaccine. 2021 Jul 10. pii: S0264-410X(21)00872.
    

    >> Share

    
    
47. FUJIMOTO AB, Keskinocak P, Yildirim I
    Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation.
    Vaccine. 2021 Jun 26. pii: S0264-410X(21)00828.
    

    >> Share

    
    
48. RAHAMIMOV N, Baturov V, Shani A, Ben Zoor I, et al
    Inadequate deltoid muscle penetration and concerns of improper COVID mRNA vaccine administration can be avoided by injection technique modification.
    Vaccine. 2021 Jul 2. pii: S0264-410X(21)00843.
    

    >> Share

    
    
49. ELAS M, Villatoro N, Pezzoli L
    Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00869.
    

    >> Share

    
    
50. LAMONTAGNE DS, Manangazira P, Marembo J, Chigodo C, et al
    HPV vaccination coverage in three districts in ZIMBABWE following national introduction of 0,12 month schedule among 10 to 14 year old girls.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00871.
    

    >> Share

    
    
51. PATHIRANA J, Kwatra G, Maposa I, Groome MJ, et al
    Effect of cytomegalovirus infection on humoral immune responses to select vaccines administered during infancy.
    Vaccine. 2021 Jul 15. pii: S0264-410X(21)00661.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share